Prime Medicine, Inc. Common Stock (PRME) Stock Forecast & Price Target
Prime Medicine, Inc. Common Stock · NASDAQ
$3.02+0.07 (+2.20%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Prime Medicine, Inc. Common Stock, 4 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $8.00 to $11.00, so the covering firms are broadly aligned. The average target of $9.50 sits 215% above the current $3.02. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.23 next quarter toward $-0.84 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy480%
Hold120%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Prime Medicine, Inc. Common Stock.
As of Jul, 4 of 5 firms rate PRME a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PRME EPS & revenue forecast
EPS · NEXT QUARTER
$-0.23
Range $-0.31 – $-0.02 · 13 analysts · -29% YoY
Next period, 13 analysts expect Prime Medicine, Inc. Common Stock to earn $-0.23 a share (range $-0.31 – $-0.02), versus $-0.32 a year earlier. Full-year consensus is $-0.99, growing to $-0.84 the year after.
REVENUE · NEXT QUARTER
$5.6M
Range $0 – $50.0M · 13 analysts · +353% YoY
Revenue is expected to reach $5.6M (range $0 – $50.0M), +353.1% year-over-year. Full-year consensus is $9.0M, rising to $18.4M next year.
Top analysts covering Prime Medicine, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PRME.
#1
Silvan Tuerkcan
JMP Securities · Rank #29
Buy
$6.00+99.0% to target
Overall win rate
50%
+ Follow
#2
Geulah Livshits
Chardan Capital · Rank #100
Buy
$9.00+198.5% to target
Overall win rate
44%
+ Follow
#3
Arthur He
HC Wainwright & Co. · Rank #150
Buy
$8.00+165.3% to target
Overall win rate
48%
+ Follow
#4
KB
Kostas Biliouris
Oppenheimer
Buy
$11.00+264.8% to target
Coverage
—
+ Follow
#5
AH
Arthur He CFA
H.C. Wainwright
Hold
No targeton PRME
Coverage
—
+ Follow
PRME stock forecast FAQ
What is PRME's average 12-month price target?+
The 2 analysts with a live target average $9.50 for Prime Medicine, Inc. Common Stock over the next 12 months, ranging from a $11.00 high to a $8.00 low.
Is PRME stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 4 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PRME?+
The Street-high target is $11.00 (Oppenheimer), and the Street-low is $8.00 (HC Wainwright & Co.). The average of all 2 active targets is $9.50.
How many Wall Street analysts cover PRME?+
5 analysts have an active rating on Prime Medicine, Inc. Common Stock, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering PRME?+
Among analysts who currently cover PRME, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Buy with a $6.00 target.
What is Prime Medicine, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.23 per share (range $-0.31 – $-0.02) across 13 analysts. Full-year EPS is projected at $-0.99, rising to $-0.84 the following year.
How much revenue is Prime Medicine, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $5.6M (range $0 – $50.0M). Full-year revenue is projected at $9.0M, growing to $18.4M next year.
Have analysts been upgrading or downgrading PRME lately?+
As of Jul, 4 of 5 firms rate PRME a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PRME calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
